Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ezogabine · Potiga, XEN496

Small molecule · Activator of KCNQ2 potassium channel (Kv7.2) (KCNQ2), KCNQ3 potassium channel (Kv7.3) (KCNQ3) and KCNQ4 potassium channel (Kv7.4) (KCNQ4) · developed by Glaxosmithkline

Approved FDA, Jun 2011
1 Registered trials

What is Ezogabine?

Ezogabine (retigabine) is a small-molecule potassium channel opener that enhances transmembrane currents through KCNQ (Kv7.2 to 7.5) channels, stabilizing the resting membrane potential and reducing brain excitability. It is studied in epilepsy, including pediatric epilepsy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Potiga, XEN496, AWD-21360, D-23129, retigabine
Drug type
Small molecule
Targets
KCNQ2 potassium channel (Kv7.2) (KCNQ2), KCNQ3 potassium channel (Kv7.3) (KCNQ3), KCNQ4 potassium channel (Kv7.4) (KCNQ4), KCNQ5 potassium channel (Kv7.5) (KCNQ5)
Mechanism
Activator of KCNQ2 potassium channel (Kv7.2) (KCNQ2), KCNQ3 potassium channel (Kv7.3) (KCNQ3) and KCNQ4 potassium channel (Kv7.4) (KCNQ4)
Pathways
potassium current enhancement, resting membrane potential stabilization, GABA-mediated currents augmentation
Therapy area
Neurology
Developer
Glaxosmithkline
In trials of
XENE
FDA status
Approved as Potiga (June 10, 2011), NDA022345 · FDA label
UNII
12G01I6BBU

✅ FDA-approved uses

From the indications section of the FDA label (version of May 20, 2016). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04912856 Phase 3 Epilepsy Terminated XENE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Brain DiseasesCentral Nervous System DiseasesDiseaseEpilepsyEpilepsy in ChildrenEpilepsy; SeizureEpileptic SyndromesNervous System Diseases

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.